Simcere has a strong product portfolio of more than 50 drugs, focusing on the treatment of tumors, cardiovascular and cerebrovascular diseases, infections and other diseases. We have a market-leading "Re-forest" brand and a "China Famous Trademark" with a separate pricing policy; The first anti-stroke drug "Bicun" that entered the China market is the first new free radical scavenger with clear action mechanism; Endo, an innovative anticancer drug of recombinant human endostatin, has patents in China and the United States, and won the 10th China Patent Gold Award and the second prize of the 2008 National Technological Invention Award. And three other brand drugs with annual sales exceeding 70 million or over 100 million: Yingtaiqing, bigi and Anqi; Among them, Yingtaiqing is another "well-known trademark in China", and in 2009 it became the promotion partner of NBA China. Anxin injection Biapenem, which was first marketed in China in 2008, provides a new treatment option for patients with moderate and severe infections in China. In 2009, antihypertensive drugs went on the market and made great strides in the field of cardiovascular treatment. In the same year, simcere successively cooperated with two biopharmaceutical companies, Shanghai Jinsai and Jiangsu Yanchang, and further entered the field of antibodies and vaccines. First of all, more brand products with strong market competitiveness are brewing.
An qi bi qi ying tai Qing
Among them, Yingtaiqing was awarded the title of "China Famous Trademark" in February 2008.